Clinical Trial · NCT06641219

Clinical Evaluation of Lutetium-177 Labeled BQ7876 for Targeting of Prostate-Specific Membrane Antigen

Overview

The study should evaluate the biological distribution of [177Lu]Lu-BQ7876 in patients with prostate cancer. The objective are: To evaluate the content of [177Lu]Lu-BQ7876 in the blood of patients with prostate cancer at different time points after a single intravenous administration. To assess the distribution of [177Lu]Lu-BQ7876 in normal tissues and tumors at different time points. To evaluate dosimetry of [177Lu]Lu-BQ7876. To study the safety and tolerability of the drug [177Lu]Lu-BQ7876 after a single injection.

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Phase

Phase 1

ClinicalTrials.gov

NCT06641219

Drug / Compound

[177Lu]Lu-BQ7876.

Isotope(s):

Target(s):

PSMA